Cytokine therapy of HIV infection

Advances in Experimental Medicine and Biology

Volumn 394, Issue , 1996, Pages 411-419

  Sneller, Michael C ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CD4 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; PENTOXIFYLLINE; RECOMBINANT ALPHA INTERFERON; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; INTRADERMAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KAPOSI SARCOMA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0029918425     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4757-9209-6_38     Document Type: Conference Paper

References (54)

1. Baron S, Tyring SK, Fleischmann WJ, et al., The interferons. Mechanisms of action and clinical applications, JAMA, 1991;266:1375-83.
2. Pitha PM, Wivel NA, Fernie BF, et al., Effect of interferon and murine leukaemia virus infection. IV. Formation of non-infectious virus in chronically infected cells, J Gen Virol, 1979;42:467-480.
3. Ho DD, Hartshorn KL, Rota TR, et al., Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro, Lancet, 1985;i:602-604.
4. Poli G, Orenstein JM, Kinter A, et al., Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines, Science, 1989;244: 575-577.
5. Francis ML, Meltzer MS, Gendelman HE, Interferons in the persistence, pathogenesis, and treatment of HIV infection, Aids Res Hum Retroviruses, 1992; 8:199-207.
6. deWit R, Schattenkerk JK, Boucher CA, et al., Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma, Lancet, 1988;ii:1218-1222.
7. Lane HC, Kovacs JA, Feinberg J, et al., Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma., Lancet, 1988;2:1218-1222.
8. Volberding PA, Mitsuyasu R, Recombinant interferon-alpha in the treatment of acquired immune deficiency syndrome related KS, Seiminars Oncol, 1985;12: 2-6.
9. Gelmann EP, Preble OT, Steis R, et al., Human lymphoblastoid interferon treatment of Kaposi's sarcoma in the acquired immune deficiency syndrome. Clinical response and prognostic parameters, Am J Med, 1985;78:737-411.
10. Groopman JE, Gottlieb MS, Goodman J, et al., Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome, Ann Intern Med, 1984;100:671-663.
11. Real FX, Oettgen HF, Krown SE, Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon, J Clin Oncol, 1986;4:544-512.
12. Lane HC, Davey V, Kovacs JA, et al., Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial., Ann Intern Med, 1990;112:805-811.
13. Jonhson VA, Barlow MA, Merrill DP, et al., Three-drug syngergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-a, J Infect Dis, 1990;161:1059-1067.
14. Kovacs JA, Deyton L, Davey R, et al., Combined zidovudine and interferon-a therapy in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS), Ann Intern Med, 1989;111:280-287.
15. Edlin BR, Weinstein RA, Whaling SM, et al., Zidovudine-interferon-alpha combination therapy in patients with advanced human immunodeficiency virus type 1 infection biphasic response of p24 antigen and quantitative polymerase chain reaction, J Infect Dis, 1992;165:793-798
16. Fischl MA, Uttamchandani RB, Resnick L, et al., A phase I study of recombinant human interferon-alpha 2a or human lymphoblastoid interferon-alpha n1 and concomitant zidovudine in patients with AIDS-related Kaposi's sarcoma. J Acquir Immune Defic Syndr, 1991;4:1-10
17. Krown SE, Gold JW, Niedzwiecki D, et al., Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS), Ann Intern Med, 1990;112:812-821.
18. Berglund O, Engman K, Ehrnst A, et al., Combined treatment of symptomatic human immunodeficiency virus type 1 infection with native interferon-alpha and zidovudine, J Infect Dis, 1991;163:710-715.
19. Hartshorn K, Neumeyer D, Vogt M, et al., Activity of interferons alpha, beta, and gamma against human immunodeficiency virus replication in vitro, AIDS Res Hum Retroviruses, 1987;112:582-589
20. Miles SA, Wang HJ, Cortes E, et al., Beta-interferon therapy in patients with poor-prognosis Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). A phase II trial with preliminary evidence of antiviral activity and low incidence of opportunistic infectio, Ann Intern Med, 1990;112:582-589
21. Lane HC, Davey RT, Sherwin SA, et al., Phase I trial of recombinant interferon-gamma in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS), J. Clin Immunol, 1989;9:351-361
22. Murray HW, Welte K, Jacobs JL, et al., Production of and in vitro response to interleukin 2 in the acquired immunodeficiency syndrome., J Clin Invest, 1985; 76:1959-1964.
23. Ciobanu N, Kruger G, Welte K, Defective T cell response to PHA and mitogenic monoclonal antibodies in male homosexuals with acquired immunodeficiency syndrome and its in vitro correction by interleukin-2, J Clin Immunol, 1983;3:332-340.
24. Gupta S, Study of activated T cells in man: Interleukin-2 receptor and transferrin receptor expression on T cells and production of interleukin-2 in patients with acquired immune deficiency syndrome, Clin Immunol Immunopathol, 1986;38:93-100.
25. Clerici M, Hakim FT, Venzon DJ, et al., Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals., J Clin Invest, 1993;91:759-765.
26. Rook AH, Hooks JJ, Quinnan GV, et al., Interleukin-2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a gamma-interferon-independent mechanism, J Immunol, 1985;134: 1503-1507
27. Ernst M, Kern P, Flad HD, et al., Effects of systemic in vivo interleukin-2 (IL-2) reconstitution in patients with acquired immune deficiency syndrome and AIDS-related complex on phenotypes and functions of peripheral blood mononuclear cells, J Clin Immunol, 1986;6:170-181.
28. Kern P, Toy J, Dietrich M, Preliminary clinical observations with recombinant interleukin-2 in patients with AIDS or LAS, Blut, 1985;50:1-6
29. Lane HC, Siegel JP, Rook AH, et al., Use of interleukin-2 in patients with acquired immunodeficiency syndrome, J Biol Response Mod, 1984;3:512-516.
30. Schwartz DH, Skowron G, Merigan TC, Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus., J Acquir Immune Defic Syndr, 1991;4:11-23.
31. Wood R, Montoya JG, Kundu SK, et al., Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/1I study, J Infect Dis, 1993; 167: 519-525.
32. McMahon DK, Armstrong JA, Huang XL, et al., A phase I study of subcutaneous recombinant interleukin-2 in patients with advanced HIV disease while on zidovudine, AIDS. 1994;8:59-66.
33. Waites L, Fyfe G, Senechek D, et al., Polyethylene glycol modified interleukin-2 (PEG IL-2) therapy in HIV seropositive individuals [abstract no PuB 7580], In: Program and abstracts: VIII International Conference on AIDS (Amsterdam), Congrex Holland BV, 1992.
34. Teppler H, Kaplan G, Smith K, et al., Efficacy of low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection, J Infect Dis, 1993;167:291-298.
35. Teppler H, Kaplan G, Smith KA, et al., Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection, J Exp Med, 1993;177:483-492.
36. Kovacs JA, Baseler M, Dewar RJ, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl J Med 1995;332:567-975.
37. Paul W, Seder R, Lymphocyte responses and cytokines, Cell, 1994;76:241-251.
38. Clerici M, Shearer G, A Th1-Th2 switch is a critical step in the etiology of HIV infection, Imunol Today, 1993;14:107-110.
39. Maggi E, Mazzetti M, Ravina A, et al., Ability of HIV to promote a TH1 to TH0 shift and to replicate preferentially in TH2 and TH0 cells, Science, 1994;265:244-248.
40. Graziosi C, Pantaleo G, Gantt KR, et al., Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals, Science, 1994;265-248-252.
41. Chehimi J, Starr SE, Frank I, et al., Impaired interleukin 12 production in human immunodeficiency virus-infected patients, J Exp Med, 1994;179:1361-1368.
42. Chehimi J, Starr SE, Frank I, et al., Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients, J Exp Med, 1992;175:789-796.
43. Clerici M, Lucey DR, Berzofsky JA, et al., Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro, Science, 1993;262:1721-1724.
44. Rieckmann P, Poli G, Fox CH, et al., Recombinant gp120 specifically enhances tumor necrosis factor-alpha production and Ig secretion in B lymphocytes from HIV-infected individuals but not from seronegative donors, J Immunol, 1991;147:2922-2927.
45. Rieckmann P, Poll G, Kehrl JH, et al., Activated B lymphocytes from human immunodeficiency virus-infected individuals induce virus expression in infected T cells and a promonocytic cell line, U1, J Exp Med, 1991, 173:1-5.
46. Poll G, Kinter A, Justement J, et al., Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression, Proc Natl Acad Sci USA, 1990;87: 782-785.
47. Sampaio EP, Moreira AL, Sarno EN, et al., Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients, J Exp Med, 1992, 175:1729-1737.
48. Fazely F, Dezube BJ, Allen RJ, et al., Pentoxifylline (Trental) decreases the replication of the human immunodeficiency virus type 1 in human peripheral blood mononuclear cells and in cultured T cells, Blood, 1991;77:1653-1656.
49. Howard OM, Clouse KA, Smith C, et al., Soluble tumor necrosis factor receptor: inhibition of human immunodeficiency virus activation, Proc Natl Acad Sci USA, 1993;90:2335-2339.
50. Murray HW. Inteferon-gamma therapy in AIDS for mononuclear phagocyte activation Biotherapy, 1990;2:149-158.
51. Smith KA. Interleukin-2: inception, impact and implications. Science, 1988;240:1169-1176.
52. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell, 1994;76:241-151.
53. Beutler B, Cerami A. The biology of cachectin/TNF-α primary mediator of the host response. Annu Rev Immunol, 1989;7:625-655.
54. Dezube BJ, Pardee AB, Beckett LA et al. Cytokine dysregulation in AIDS: in vivo overexpression of mRNA of tumor necrosis factor-alpha and its correlation with that of the inflammatory cytocine GRO. J Acquir Immune Defic Syndr, 1992;5:1099-1104.